APO Research
Talk to an analyst

APO RESEARCH · REPORT

Malignant Mesothelioma Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Malignant Mesothelioma Drugs Industry Research Report 2026

20 December 2025150 pages

Choose your research edition.

Industry ResearchMalignant Mesothelioma Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Malignant Mesothelioma Drugs Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Malignant Mesothelioma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malignant Mesothelioma Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Malignant Mesothelioma Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Malignant Mesothelioma Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Malignant Mesothelioma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Malignant Mesothelioma Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Malignant Mesothelioma Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Malignant Mesothelioma Drugs include Teva Pharmaceuticals, Sun Pharmaceuticals, Sanofi, Novartis, Merck, Mylan, Roche, Eli Lilly and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Malignant Mesothelioma Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Malignant Mesothelioma Drugs Market by Company

Teva Pharmaceuticals

Sun Pharmaceuticals

Sanofi

Novartis

Merck

Mylan

Roche

Eli Lilly

Pfizer

Fresenius Kabi

AstraZeneca

Polaris Pharmaceuticals

Ono Pharmaceutical

Nichi-Iko Pharmaceutical

MolMed

Kyowa Hakko Kirin

Corden Pharma

Concordia International

Bristol-Myers Squibb

Boehringer Ingelheim GmbH

Malignant Mesothelioma Drugs Segment by Type

Vinorelbine

Cisplatin

Pemetrexed

Carboplatin

Gemcitabine

Others

Malignant Mesothelioma Drugs Segment by Application

Retail Pharmacies

Hospital Pharmacies

Oncology Centers

Others

Malignant Mesothelioma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Malignant Mesothelioma Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Malignant Mesothelioma Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Malignant Mesothelioma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Malignant Mesothelioma Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Malignant Mesothelioma Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Malignant Mesothelioma Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Malignant Mesothelioma Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Malignant Mesothelioma Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Malignant Mesothelioma Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Malignant Mesothelioma Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Malignant Mesothelioma Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Malignant Mesothelioma Drugs, Product Type & Application Table 14. Global Malignant Mesothelioma Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Malignant Mesothelioma Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Pharmaceuticals Company Information Table 19. Teva Pharmaceuticals Business Overview Table 20. Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 22. Teva Pharmaceuticals Recent Developments Table 23. Sun Pharmaceuticals Company Information Table 24. Sun Pharmaceuticals Business Overview Table 25. Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 27. Sun Pharmaceuticals Recent Developments Table 28. Sanofi Company Information Table 29. Sanofi Business Overview Table 30. Sanofi Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Sanofi Malignant Mesothelioma Drugs Product Portfolio Table 32. Sanofi Recent Developments Table 33. Novartis Company Information Table 34. Novartis Business Overview Table 35. Novartis Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Novartis Malignant Mesothelioma Drugs Product Portfolio Table 37. Novartis Recent Developments Table 38. Merck Company Information Table 39. Merck Business Overview Table 40. Merck Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Merck Malignant Mesothelioma Drugs Product Portfolio Table 42. Merck Recent Developments Table 43. Mylan Company Information Table 44. Mylan Business Overview Table 45. Mylan Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Mylan Malignant Mesothelioma Drugs Product Portfolio Table 47. Mylan Recent Developments Table 48. Roche Company Information Table 49. Roche Business Overview Table 50. Roche Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Roche Malignant Mesothelioma Drugs Product Portfolio Table 52. Roche Recent Developments Table 53. Eli Lilly Company Information Table 54. Eli Lilly Business Overview Table 55. Eli Lilly Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Eli Lilly Malignant Mesothelioma Drugs Product Portfolio Table 57. Eli Lilly Recent Developments Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Pfizer Malignant Mesothelioma Drugs Product Portfolio Table 62. Pfizer Recent Developments Table 63. Fresenius Kabi Company Information Table 64. Fresenius Kabi Business Overview Table 65. Fresenius Kabi Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio Table 67. Fresenius Kabi Recent Developments Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. AstraZeneca Malignant Mesothelioma Drugs Product Portfolio Table 72. AstraZeneca Recent Developments Table 73. Polaris Pharmaceuticals Company Information Table 74. Polaris Pharmaceuticals Business Overview Table 75. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio Table 77. Polaris Pharmaceuticals Recent Developments Table 78. Ono Pharmaceutical Company Information Table 79. Ono Pharmaceutical Business Overview Table 80. Ono Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 82. Ono Pharmaceutical Recent Developments Table 83. Nichi-Iko Pharmaceutical Company Information Table 84. Nichi-Iko Pharmaceutical Business Overview Table 85. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio Table 87. Nichi-Iko Pharmaceutical Recent Developments Table 88. MolMed Company Information Table 89. MolMed Business Overview Table 90. MolMed Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. MolMed Malignant Mesothelioma Drugs Product Portfolio Table 92. MolMed Recent Developments Table 93. Kyowa Hakko Kirin Company Information Table 94. Kyowa Hakko Kirin Business Overview Table 95. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio Table 97. Kyowa Hakko Kirin Recent Developments Table 98. Corden Pharma Company Information Table 99. Corden Pharma Business Overview Table 100. Corden Pharma Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Corden Pharma Malignant Mesothelioma Drugs Product Portfolio Table 102. Corden Pharma Recent Developments Table 103. Concordia International Company Information Table 104. Concordia International Business Overview Table 105. Concordia International Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Concordia International Malignant Mesothelioma Drugs Product Portfolio Table 107. Concordia International Recent Developments Table 108. Bristol-Myers Squibb Company Information Table 109. Bristol-Myers Squibb Business Overview Table 110. Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio Table 112. Bristol-Myers Squibb Recent Developments Table 113. Boehringer Ingelheim GmbH Company Information Table 114. Boehringer Ingelheim GmbH Business Overview Table 115. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio Table 117. Boehringer Ingelheim GmbH Recent Developments Table 118. Global Malignant Mesothelioma Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Malignant Mesothelioma Drugs Sales by Region (2021-2026) & (K Units) Table 120. Global Malignant Mesothelioma Drugs Sales Market Share by Region (2021-2026) Table 121. Global Malignant Mesothelioma Drugs Sales by Region (2027-2032) & (K Units) Table 122. Global Malignant Mesothelioma Drugs Sales Market Share by Region (2027-2032) Table 123. Global Malignant Mesothelioma Drugs Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Malignant Mesothelioma Drugs Revenue Market Share by Region (2021-2026) Table 125. Global Malignant Mesothelioma Drugs Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Malignant Mesothelioma Drugs Revenue Market Share by Region (2027-2032) Table 127. North America Malignant Mesothelioma Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 129. North America Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 130. North America Malignant Mesothelioma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Malignant Mesothelioma Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Malignant Mesothelioma Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 134. Europe Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 135. Europe Malignant Mesothelioma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Malignant Mesothelioma Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Malignant Mesothelioma Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 139. Asia Pacific Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 140. Asia Pacific Malignant Mesothelioma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Malignant Mesothelioma Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Malignant Mesothelioma Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 144. South America Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 145. South America Malignant Mesothelioma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Malignant Mesothelioma Drugs Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Malignant Mesothelioma Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Malignant Mesothelioma Drugs Sales by Country (2021-2026) & (K Units) Table 149. Middle East and Africa Malignant Mesothelioma Drugs Sales by Country (2027-2032) & (K Units) Table 150. Middle East and Africa Malignant Mesothelioma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Malignant Mesothelioma Drugs Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Malignant Mesothelioma Drugs Sales by Type (2021-2026) & (K Units) Table 153. Global Malignant Mesothelioma Drugs Sales by Type (2027-2032) & (K Units) Table 154. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2021-2026) Table 155. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2027-2032) Table 156. Global Malignant Mesothelioma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Malignant Mesothelioma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2026) Table 159. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2027-2032) Table 160. Global Malignant Mesothelioma Drugs Price by Type (2021-2026) & (US$/Unit) Table 161. Global Malignant Mesothelioma Drugs Price by Type (2027-2032) & (US$/Unit) Table 162. Global Malignant Mesothelioma Drugs Sales by Application (2021-2026) & (K Units) Table 163. Global Malignant Mesothelioma Drugs Sales by Application (2027-2032) & (K Units) Table 164. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2021-2026) Table 165. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2027-2032) Table 166. Global Malignant Mesothelioma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Malignant Mesothelioma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2021-2026) Table 169. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2027-2032) Table 170. Global Malignant Mesothelioma Drugs Price by Application (2021-2026) & (US$/Unit) Table 171. Global Malignant Mesothelioma Drugs Price by Application (2027-2032) & (US$/Unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Malignant Mesothelioma Drugs Distributors List Table 175. Malignant Mesothelioma Drugs Customers List Table 176. Malignant Mesothelioma Drugs Industry Trends Table 177. Malignant Mesothelioma Drugs Industry Drivers Table 178. Malignant Mesothelioma Drugs Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Malignant Mesothelioma Drugs Product Image Figure 5. Global Malignant Mesothelioma Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Malignant Mesothelioma Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Malignant Mesothelioma Drugs Sales (2021-2032) & (K Units) Figure 8. Global Malignant Mesothelioma Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Vinorelbine Product Image Figure 10. Cisplatin Product Image Figure 11. Pemetrexed Product Image Figure 12. Carboplatin Product Image Figure 13. Gemcitabine Product Image Figure 14. Others Product Image Figure 15. Retail Pharmacies Product Image Figure 16. Hospital Pharmacies Product Image Figure 17. Oncology Centers Product Image Figure 18. Others Product Image Figure 19. Global Malignant Mesothelioma Drugs Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Malignant Mesothelioma Drugs, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Malignant Mesothelioma Drugs Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Malignant Mesothelioma Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Malignant Mesothelioma Drugs Sales by Region in 2025 Figure 25. Global Malignant Mesothelioma Drugs Revenue by Region in 2025 Figure 26. North America Malignant Mesothelioma Drugs Market Size by Country in 2025 Figure 27. North America Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2032) Figure 28. North America Malignant Mesothelioma Drugs Revenue Market Share by Country (2021-2032) Figure 29. United States Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Malignant Mesothelioma Drugs Market Size by Country in 2025 Figure 32. Europe Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2032) Figure 33. Europe Malignant Mesothelioma Drugs Revenue Market Share by Country (2021-2032) Figure 34. Germany Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Nordic Countries Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Malignant Mesothelioma Drugs Market Size by Country in 2025 Figure 41. Asia Pacific Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Malignant Mesothelioma Drugs Revenue Market Share by Country (2021-2032) Figure 43. China Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. China Taiwan Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Malignant Mesothelioma Drugs Market Size by Country in 2025 Figure 52. South America Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2032) Figure 53. South America Malignant Mesothelioma Drugs Revenue Market Share by Country (2021-2032) Figure 54. Mexico Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Brazil Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Malignant Mesothelioma Drugs Market Size by Country in 2025 Figure 58. Middle East and Africa Malignant Mesothelioma Drugs Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Malignant Mesothelioma Drugs Revenue Market Share by Country (2021-2032) Figure 60. Turkey Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. UAE Malignant Mesothelioma Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Global Malignant Mesothelioma Drugs Sales Market Share by Type (2021-2032) Figure 64. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2032) Figure 65. Global Malignant Mesothelioma Drugs Price (US$/Unit) by Type (2021-2032) Figure 66. Global Malignant Mesothelioma Drugs Sales Market Share by Application (2021-2032) Figure 67. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2021-2032) Figure 68. Global Malignant Mesothelioma Drugs Price (US$/Unit) by Application (2021-2032) Figure 69. Malignant Mesothelioma Drugs Value Chain Figure 70. Malignant Mesothelioma Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Malignant Mesothelioma Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Vinorelbine
  • Cisplatin
  • Pemetrexed
  • Carboplatin
  • Gemcitabine
  • Others
Applications
  • Retail Pharmacies
  • Hospital Pharmacies
  • Oncology Centers
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Sanofi
  • Novartis
  • Merck
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • Fresenius Kabi
  • AstraZeneca
  • Polaris Pharmaceuticals
  • Ono Pharmaceutical
  • Nichi-Iko Pharmaceutical
  • MolMed
  • Kyowa Hakko Kirin
  • Corden Pharma
  • Concordia International
  • Bristol-Myers Squibb
  • Boehringer Ingelheim GmbH

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Malignant Mesothelioma Drugs Market Size (2021-2032)
  4. 2.2.2 Global Malignant Mesothelioma Drugs Sales (2021-2032)
  5. 2.2.3 Global Malignant Mesothelioma Drugs Market Average Price (2021-2032)
  6. 2.3 Malignant Mesothelioma Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Vinorelbine
  9. 2.3.3 Cisplatin
  10. 2.3.4 Pemetrexed
  11. 2.3.5 Carboplatin
  12. 2.3.6 Gemcitabine
  13. 2.3.7 Others
  14. 2.4 Malignant Mesothelioma Drugs by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Retail Pharmacies
  17. 2.4.3 Hospital Pharmacies
  18. 2.4.4 Oncology Centers
  19. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Malignant Mesothelioma Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Malignant Mesothelioma Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Malignant Mesothelioma Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Malignant Mesothelioma Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Malignant Mesothelioma Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Malignant Mesothelioma Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Malignant Mesothelioma Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Malignant Mesothelioma Drugs, Established Date
  9. 3.9 Global Malignant Mesothelioma Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceuticals
  2. 4.1.1 Teva Pharmaceuticals Company Information
  3. 4.1.2 Teva Pharmaceuticals Business Overview
  4. 4.1.3 Teva Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  6. 4.1.5 Teva Pharmaceuticals Recent Developments
  7. 4.2 Sun Pharmaceuticals
  8. 4.2.1 Sun Pharmaceuticals Company Information
  9. 4.2.2 Sun Pharmaceuticals Business Overview
  10. 4.2.3 Sun Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sun Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  12. 4.2.5 Sun Pharmaceuticals Recent Developments
  13. 4.3 Sanofi
  14. 4.3.1 Sanofi Company Information
  15. 4.3.2 Sanofi Business Overview
  16. 4.3.3 Sanofi Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sanofi Malignant Mesothelioma Drugs Product Portfolio
  18. 4.3.5 Sanofi Recent Developments
  19. 4.4 Novartis
  20. 4.4.1 Novartis Company Information
  21. 4.4.2 Novartis Business Overview
  22. 4.4.3 Novartis Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis Malignant Mesothelioma Drugs Product Portfolio
  24. 4.4.5 Novartis Recent Developments
  25. 4.5 Merck
  26. 4.5.1 Merck Company Information
  27. 4.5.2 Merck Business Overview
  28. 4.5.3 Merck Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Merck Malignant Mesothelioma Drugs Product Portfolio
  30. 4.5.5 Merck Recent Developments
  31. 4.6 Mylan
  32. 4.6.1 Mylan Company Information
  33. 4.6.2 Mylan Business Overview
  34. 4.6.3 Mylan Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Mylan Malignant Mesothelioma Drugs Product Portfolio
  36. 4.6.5 Mylan Recent Developments
  37. 4.7 Roche
  38. 4.7.1 Roche Company Information
  39. 4.7.2 Roche Business Overview
  40. 4.7.3 Roche Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Roche Malignant Mesothelioma Drugs Product Portfolio
  42. 4.7.5 Roche Recent Developments
  43. 4.8 Eli Lilly
  44. 4.8.1 Eli Lilly Company Information
  45. 4.8.2 Eli Lilly Business Overview
  46. 4.8.3 Eli Lilly Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Eli Lilly Malignant Mesothelioma Drugs Product Portfolio
  48. 4.8.5 Eli Lilly Recent Developments
  49. 4.9 Pfizer
  50. 4.9.1 Pfizer Company Information
  51. 4.9.2 Pfizer Business Overview
  52. 4.9.3 Pfizer Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Pfizer Malignant Mesothelioma Drugs Product Portfolio
  54. 4.9.5 Pfizer Recent Developments
  55. 4.10 Fresenius Kabi
  56. 4.10.1 Fresenius Kabi Company Information
  57. 4.10.2 Fresenius Kabi Business Overview
  58. 4.10.3 Fresenius Kabi Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Fresenius Kabi Malignant Mesothelioma Drugs Product Portfolio
  60. 4.10.5 Fresenius Kabi Recent Developments
  61. 4.11 AstraZeneca
  62. 4.11.1 AstraZeneca Company Information
  63. 4.11.2 AstraZeneca Business Overview
  64. 4.11.3 AstraZeneca Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 AstraZeneca Malignant Mesothelioma Drugs Product Portfolio
  66. 4.11.5 AstraZeneca Recent Developments
  67. 4.12 Polaris Pharmaceuticals
  68. 4.12.1 Polaris Pharmaceuticals Company Information
  69. 4.12.2 Polaris Pharmaceuticals Business Overview
  70. 4.12.3 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product Portfolio
  72. 4.12.5 Polaris Pharmaceuticals Recent Developments
  73. 4.13 Ono Pharmaceutical
  74. 4.13.1 Ono Pharmaceutical Company Information
  75. 4.13.2 Ono Pharmaceutical Business Overview
  76. 4.13.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Ono Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  78. 4.13.5 Ono Pharmaceutical Recent Developments
  79. 4.14 Nichi-Iko Pharmaceutical
  80. 4.14.1 Nichi-Iko Pharmaceutical Company Information
  81. 4.14.2 Nichi-Iko Pharmaceutical Business Overview
  82. 4.14.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product Portfolio
  84. 4.14.5 Nichi-Iko Pharmaceutical Recent Developments
  85. 4.15 MolMed
  86. 4.15.1 MolMed Company Information
  87. 4.15.2 MolMed Business Overview
  88. 4.15.3 MolMed Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 MolMed Malignant Mesothelioma Drugs Product Portfolio
  90. 4.15.5 MolMed Recent Developments
  91. 4.16 Kyowa Hakko Kirin
  92. 4.16.1 Kyowa Hakko Kirin Company Information
  93. 4.16.2 Kyowa Hakko Kirin Business Overview
  94. 4.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product Portfolio
  96. 4.16.5 Kyowa Hakko Kirin Recent Developments
  97. 4.17 Corden Pharma
  98. 4.17.1 Corden Pharma Company Information
  99. 4.17.2 Corden Pharma Business Overview
  100. 4.17.3 Corden Pharma Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Corden Pharma Malignant Mesothelioma Drugs Product Portfolio
  102. 4.17.5 Corden Pharma Recent Developments
  103. 4.18 Concordia International
  104. 4.18.1 Concordia International Company Information
  105. 4.18.2 Concordia International Business Overview
  106. 4.18.3 Concordia International Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Concordia International Malignant Mesothelioma Drugs Product Portfolio
  108. 4.18.5 Concordia International Recent Developments
  109. 4.19 Bristol-Myers Squibb
  110. 4.19.1 Bristol-Myers Squibb Company Information
  111. 4.19.2 Bristol-Myers Squibb Business Overview
  112. 4.19.3 Bristol-Myers Squibb Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Bristol-Myers Squibb Malignant Mesothelioma Drugs Product Portfolio
  114. 4.19.5 Bristol-Myers Squibb Recent Developments
  115. 4.20 Boehringer Ingelheim GmbH
  116. 4.20.1 Boehringer Ingelheim GmbH Company Information
  117. 4.20.2 Boehringer Ingelheim GmbH Business Overview
  118. 4.20.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product Portfolio
  120. 4.20.5 Boehringer Ingelheim GmbH Recent Developments
5 Global Malignant Mesothelioma Drugs Market Scenario by Region
  1. 5.1 Global Malignant Mesothelioma Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Malignant Mesothelioma Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Malignant Mesothelioma Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Malignant Mesothelioma Drugs Sales by Region: 2027-2032
  5. 5.3 Global Malignant Mesothelioma Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Malignant Mesothelioma Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Malignant Mesothelioma Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Malignant Mesothelioma Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Malignant Mesothelioma Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Malignant Mesothelioma Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Malignant Mesothelioma Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Malignant Mesothelioma Drugs Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Malignant Mesothelioma Drugs Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Malignant Mesothelioma Drugs Market Facts & Figures by Country
  36. 5.7.1 South America Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  38. 5.7.3 South America Malignant Mesothelioma Drugs Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.8 Middle East and Africa Malignant Mesothelioma Drugs Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Malignant Mesothelioma Drugs Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Malignant Mesothelioma Drugs Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Malignant Mesothelioma Drugs Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Malignant Mesothelioma Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Malignant Mesothelioma Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Malignant Mesothelioma Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Malignant Mesothelioma Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Malignant Mesothelioma Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Malignant Mesothelioma Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Malignant Mesothelioma Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Malignant Mesothelioma Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Malignant Mesothelioma Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Malignant Mesothelioma Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Malignant Mesothelioma Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Malignant Mesothelioma Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Malignant Mesothelioma Drugs Value Chain Analysis
  2. 8.1.1 Malignant Mesothelioma Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Malignant Mesothelioma Drugs Production Mode & Process
  5. 8.2 Malignant Mesothelioma Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Malignant Mesothelioma Drugs Distributors
  8. 8.2.3 Malignant Mesothelioma Drugs Customers
9 Global Malignant Mesothelioma Drugs Analyzing Market Dynamics
  1. 9.1 Malignant Mesothelioma Drugs Industry Trends
  2. 9.2 Malignant Mesothelioma Drugs Industry Drivers
  3. 9.3 Malignant Mesothelioma Drugs Industry Opportunities and Challenges
  4. 9.4 Malignant Mesothelioma Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst